TWO SIGMA INVESTMENTS, LP - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 233 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.

Quarter-by-quarter ownership
TWO SIGMA INVESTMENTS, LP ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$341,376
-98.3%
25,400
-97.9%
0.00%
-98.2%
Q1 2023$19,637,767
-45.2%
1,184,425
-38.5%
0.06%
-50.0%
Q4 2022$35,806,674
+60.9%
1,925,090
+11.0%
0.11%
+47.4%
Q3 2022$22,256,000
+585.2%
1,734,723
+274.4%
0.08%
+590.9%
Q2 2022$3,248,000
-63.6%
463,325
-56.9%
0.01%
-57.7%
Q1 2022$8,914,000
+73.0%
1,075,282
+41.3%
0.03%
+136.4%
Q4 2021$5,153,000
+748.9%
761,079
+564.3%
0.01%
+1000.0%
Q3 2021$607,000
-69.5%
114,571
-66.9%
0.00%
-80.0%
Q2 2021$1,990,000
-25.7%
346,065
-40.5%
0.01%
-28.6%
Q1 2021$2,680,000
+117.4%
581,253
+57.5%
0.01%
+75.0%
Q4 2020$1,233,000
-37.4%
369,071
-13.4%
0.00%
-60.0%
Q2 2020$1,969,000
+3838.0%
426,197
+3160.6%
0.01%
Q1 2020$50,000
-98.1%
13,071
-98.2%
0.00%
-100.0%
Q4 2019$2,673,000
+886.3%
712,757
+405.5%
0.01%
+700.0%
Q4 2018$271,000
+298.5%
141,004
+550.6%
0.00%
Q2 2018$68,000
+51.1%
21,673
+15.9%
0.00%
Q1 2018$45,000
-97.2%
18,703
-95.4%
0.00%
-100.0%
Q4 2017$1,592,000
+2111.1%
407,175
+562.8%
0.01%
Q1 2016$72,00061,4340.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Consonance Capital Management LP 5,517,885$22,789,0002.29%
March Altus Capital Management LP 80,890$334,0001.94%
TANAKA CAPITAL MANAGEMENT INC 111,693$462,0001.15%
PURA VIDA INVESTMENTS, LLC 395,000$1,951,0001.00%
Broadfin Capital, LLC 4,183,177$17,277,0000.93%
Catalyst Capital Advisors LLC 1,310,000$5,411,0000.63%
SPHERA FUNDS MANAGEMENT LTD. 1,200,000$4,956,0000.48%
Baker Brothers Advisors 7,335,692$30,296,0000.27%
TURNER INVESTMENTS LLC 286,370$1,183,0000.22%
Perceptive Advisors 851,200$3,515,0000.21%
View complete list of CATALYST PHARMACEUTICALS INC shareholders